Jounce Therapeutics Profit Margin

Jounce Therapeutics (JNCE) currently reports a profit margin of -62.1% as of December 2022. That compares with -225.25% in the prior-year period — up 72.4% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Jounce Therapeutics's profit margin history and peer comparisons.

Jounce Therapeutics's profit margin increased from -225.25% to -62.1% — a 72.4% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Jounce Therapeutics's profit margin of -62.1% is lower than the Healthcare sector average of 13.89%. That is roughly 547.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Jounce Therapeutics's current -62.1% should be judged against Healthcare norms (sector average: 13.89%) and against JNCE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -62.1%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Jounce Therapeutics, and consider following JNCE for alerts when major investors trade the stock.